Neogen(US:NEOG) ZACKS·2025-10-06 14:15Core Insights - Neogen (NEOG) is expected to report quarterly earnings of $0.05 per share, a decline of 28.6% year-over-year, with revenues forecasted at $203.18 million, reflecting a decrease of 6.4% compared to the same period last year [1] Earnings Estimates - The consensus EPS estimate for the quarter has not changed over the past 30 days, indicating that analysts have not revised their initial projections [2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3] Revenue Projections - Analysts predict specific revenue figures for Neogen's segments: - 'Revenues- Food Safety- Natural Toxins & Allergens' estimated at $18.68 million, down 8.3% year-over-year [5] - 'Revenues- Food Safety- Bacterial & General Sanitation' expected to reach $38.70 million, a decrease of 3% [5] - 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' projected at $76.43 million, down 6.5% [6] - 'Revenues- Animal Safety- Veterinary Instruments & Disposables' forecasted at $13.94 million, an increase of 11.3% [6] - 'Revenues- Animal Safety- Animal Care & Other' expected to be $8.16 million, up 22.1% year-over-year [7] - 'Revenues- Food Safety' projected at $146.62 million, down 8% [7] - 'Revenues- Animal Safety- Genomics Services' estimated at $4.42 million, a significant decline of 72.2% [7] - 'Revenues- Food Safety- Genomics Services' expected at $13.26 million, a substantial increase of 137.3% [8] - 'Revenues- Animal Safety' forecasted at $54.65 million, down 5.2% year-over-year [8] Stock Performance - Neogen shares have increased by 5.4% over the past month, outperforming the Zacks S&P 500 composite, which rose by 4.3% [8] - Neogen holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near term [8]